Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: A consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange

Diabetes Care

Volumn 40, Issue 12, 2017, Pages 1622-1630

  Agiostratidou, Gina ^a   Anhalt, Henry ^b   Ball, Dana ^b   Blonde, Lawrence ^c   Gourgari, Evgenia ^d   Harriman, Karen N ^e   Kowalski, Aaron J ^f   Madden, Paul ^g   McAuliffe Fogarty, Alicia H ^g   McElwee Malloy, Molly ^e   Peters, Anne ^d   Raman, Sripriya ^c   Reifschneider, Kent ^h   Rubin, Karen ^h   Weinzimer, Stuart A ^h  

^a The Leona M and Harry B Helmsley Charitable Trust   (United States)

^b T1D Exchange   (United States)

^c American Association of Clinical Endocrinologists   (United States)

^d Harvard Medical School   (United States)

^e American Association of Diabetes Educators   (United States)

^f JDRF International   (United States)

^g AMERICAN DIABETES ASSOCIATION   (United States)

^h Pediatric Endocrine Society   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PROTHROMBIN; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; BLOOD GLUCOSE MONITORING; BLURRED VISION; CLINICAL PRACTICE; COGNITION; CONFUSION; DECISION MAKING; DIABETIC KETOACIDOSIS; DISEASE BURDEN; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE ORGANIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MEDICAL SOCIETY; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PREFRONTAL CORTEX; PRIMARY MEDICAL CARE; QUALITY OF LIFE; TREMOR; BLOOD; EDUCATION; ENDOCRINOLOGIST; ENDOCRINOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; STANDARDS; UNITED STATES;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; ENDOCRINOLOGISTS; ENDOCRINOLOGY; GLYCATED HEMOGLOBIN A; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; OUTCOME ASSESSMENT (HEALTH CARE); SOCIETIES, MEDICAL; UNITED STATES;

EID: 85033204449     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1624     Document Type: Article

References (79)

1. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978
2. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012;97:4383-4389
3. Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care 2005;28:2361-2366
4. Canadian Agency for Drugs and Technologies in Health. HbA1c testing frequency: a review of the clinical evidence and guidelines [Internet], 2014. Available from https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0069851/pdf/PubMedHealth-PMH0069851.pdf. Accessed 26 May 2017
5. U.S. Food and Drug Administration. Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention [Internet], 2008. Available from https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071624.pdf. Accessed 26 May 2017
6. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet], 2012. Available from http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500129256.pdf. Accessed 10 October 2017
7. Parrish RG. Measuring population health outcomes [article online]. Prev Chronic Dis 2010;7: A71. Available from http://www.cdc.gov/pcd/issues/2010/jul/10-0005.htm. Accessed 29 August 2017
8. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care 2017;40:1631-1640
9. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-3176
10. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 2015;38: 316-322
11. Lu C-L, Shen H-N, Hu SC, Wang J-D, Li C-Y. A population-based study of all-causemortality and cardiovascular disease in association with prior history of hypoglycemia among patients with type 1 diabetes. Diabetes Care 2016;39:1571-1578
12. Alsahli M, Gerich JE. Hypoglycemia. Endocrinol Metab Clin North Am 2013;42:657-676
13. Orchard TJ, Nathan DM, Zinman B, et al.; Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45-53
14. Tanenberg RJ, Newton CA, Drake AJ III. Confirmation of hypoglycemia in the "dead-in-bed" syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract 2010;16:244-248
15. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-1912
16. Cryer PE. The prevention and correction of hypoglycemia. In Handbook of Physiology: A Critical, Comprehensive Presentation of Physiological Knowledge and Concepts. Sec. 7, Vol 2. Jefferson L, Cherrington A, Eds. New York, Oxford University Press, 2001, p. 1057-1092
17. Moheet A, Kumar A, Eberly LE, Kim J, Roberts R, Seaquist ER. Hypoglycemia-associated autonomic failure in healthy humans: comparison of two vs three periods of hypoglycemia on hypoglycemiainduced counterregulatory and symptom response 5 days later. J Clin Endocrinol Metab 2014;99:664-670
18. Sprague JE, Arbeláez AM. Glucose counterregulatory responses to hypoglycemia. Pediatr Endocrinol Rev 2011;9:463-475
19. Graveling AJ, Deary IJ, Frier BM. Acute hypoglycemia impairs executive cognitive function in adults with and without type 1 diabetes. Diabetes Care 2013;36:3240-3246
20. van de Ven KCC, Tack CJ, Heerschap A, van der Graaf M, de Galan BE. Patients with type 1 diabetes exhibit altered cerebral metabolism during hypoglycemia. J Clin Invest 2013;123:623-629
21. Bolo NR, Musen G, Simonson DC, et al. Functional connectivity of insula, basal ganglia, and prefrontal executive control networks during hypoglycemia in type 1 diabetes. J Neurosci 2015;35: 11012-11023
22. Hershey T, Bhargava N, Sadler M, White NH, Craft S. Conventional versus intensive diabetes therapy in children with type 1 diabetes: effects on memory and motor speed. Diabetes Care 1999;22:1318-1324
23. Allen KV, Pickering MJ, Zammitt NN, et al. Effects of acute hypoglycemia on working memory and language processing in adults with and without type 1 diabetes. Diabetes Care 2015;38: 1108-1115
24. Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, et al. Cognitive function is disrupted by both hypo-and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care 2009;32:1001-1006
25. Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310:1240-1247
26. Joy NG, Tate DB, Younk LM, Davis SN. Effects of acute and antecedent hypoglycemia on endothelial function and markers of atherothrombotic balance in healthy humans. Diabetes 2015;64: 2571-2580
27. Feldman J, Barshi I. The effects of blood glucose levels on cognitive performance: a review of the literature [Internet], 2007. NASA Scientific and Technical Information (STI) Program Office. Available from https://ntrs.nasa.gov/archive/nasa/casi.ntrs.nasa.gov/20070031714.pdf. Accessed 22 November 2016
28. Reno CM, Litvin M, Clark AL, Fisher SJ. Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments. Endocrinol Metab Clin North Am 2013;42:15-38
29. Nelson JM, Dufraux K, Cook PF. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc 2007;55:2041-2044
30. Pedersen-Bjergaard U, Færch L, Allingbjerg M-L, Agesen R, Thorsteinsson B. The influence of new European Union driver's license legislation on reporting of severe hypoglycemia by patientswith type 1 diabetes. Diabetes Care 2015;38:29-33
31. Lehecka KE, Renukuntla VS, Heptulla RA. Insight into hypoglycemia in pediatric type 1 diabetesmellitus. Int J Pediatr Endocrinol 2012;2012:19
32. Kubiak T, Hermanns N, Schreckling HJ, Kulzer B, Haak T. Assessment of hypoglycaemia awareness using continuous glucosemonitoring. Diabet Med 2004;21:487-490
33. Harris SB, Khunti K, Landin-Olsson M, et al. Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Prefer Adherence 2013;7:925-936
34. McNay EC, Cotero VE. Mini-review: impact of recurrent hypoglycemia on cognitive and brain function. Physiol Behav 2010;100:234-238
35. Davis SN, Mann S, Galassetti P, et al. Effects of differing durations of antecedent hypoglycemia on counterregulatory responses to subsequent hypoglycemia in normal humans. Diabetes 2000; 49:1897-1903
36. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017;40:155-157
37. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl. 1):S62-S69
38. White M, Zacharin MR, Werther GA, Cameron FJ. Intravenous glucagon in a deliberate insulin overdose in an adolescent with type 1 diabetes mellitus. Pediatr Diabetes 2016;17:66-69
39. Harrell RM, Orzeck EA; American Association of Clinical Endocrinologists Socioeconomics and Member Advocacy Committee. Coding guidelines for continuous glucose monitoring. Endocr Pract 2010;16:151-154
40. Nathan DM, Genuth S, Lachin J, et al.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
41. Nathan DM, Cleary PA, Backlund J-YC, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
42. Khaw K-T, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141:413-420
43. Erqou S, Lee C-TC, Suffoletto M, et al. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis. Eur J Heart Fail 2013;15:185-193
44. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. NEngl J Med 2008; 359:1577-1589
45. Witte DR, Tesfaye S, Chaturvedi N, Eaton SE, Kempler P, Fuller JH; EURODIAB Prospective Complications Study Group. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005;48:164-171
46. White NH, Sun W, Cleary PA, et al.; DCCTEDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010;59:1244-1253
47. Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65
48. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 1997;314:1303-1306
49. Jørgensen H, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke 1994;25:1977-1984
50. Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med 1983; 74:540-544
51. Klemp K, Larsen M, Sander B, Vaag A, Brockhoff PB, Lund-Andersen H. Effect of shortterm hyperglycemia on multifocal electroretinogram in diabetic patients without retinopathy. Invest Ophthalmol Vis Sci 2004;45:3812-3819
52. Freckmann G, Hagenlocher S, Baumstark A, et al. Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals. J Diabetes Sci Technol 2007;1:695-703
53. Borg R, Kuenen JC, Carstensen B, et al.; ADAG Study Group. Real-life glycaemic profiles in nondiabetic individuals with low fasting glucose and normal HbA1c: the A1C-Derived Average Glucose (ADAG) study. Diabetologia 2010;53:1608-1611
54. Mazze RS, Strock E, Wesley D, et al. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther 2008;10:149-159
55. American Diabetes Association. Glycemic targets. Sec. 6. In Standards of Medical Care in Diabetesd2017 [Published correction appears in Diabetes Care 2017;40:985]. Diabetes Care 2017;40(Suppl. 1):S48-S56
56. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015d executive summary. Endocr Pract 2015;21(Suppl. 1):1-87
57. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438-447
58. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-1343
59. Fonseca VA, Grunberger G, Anhalt H, et al.; Consensus Conference Writing Committee. Continuous glucose monitoring: a consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract 2016;22:1008-1021
60. Kuenen JC, Borg R, Kuik DJ, et al.; ADAG Study Group. Does glucose variability influence the relationship between mean plasma glucose and HbA1c levels in type 1 and type 2 diabetic patients? Diabetes Care 2011;34:1843-1847
61. Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 2003;26:163-167
62. Ali MK, Feeney P, Hire D, et al. Glycaemia and correlates of patient-reported outcomes in ACCORD trial participants. Diabet Med 2012;29:e67-e74
63. Omar AS, Salama A, Allam M, et al. Association of time in blood glucose range with outcomes following cardiac surgery. BMC Anesthesiol 2015;15:14
64. Rickels MR, Peleckis AJ, Markmann E, et al. Long-term improvement in glucose controls and counterregulation by islet transplantation for type 1 diabetes. J Clin Endocrinol Metab 2016; 101:4421-4430
65. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313-325
66. Wang Y-M, Zhao L-H, Su J-B, et al. Glycemic variability in normal glucose tolerance women with the previous gestational diabetes mellitus. Diabetol Metab Syndr 2015;7:82
67. Ayano-Takahara S, Ikeda K, Fujimoto S, et al. Carbohydrate intake is associated with time spent in the euglycemic range in patients with type 1 diabetes. J Diabetes Investig 2015;6:678-686
68. Ly TT, Roy A, Grosman B, et al. Day and night closed-loop control using the integrated medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. Diabetes Care 2015;38:1205-1211
69. Maletkovic J, Drexler A. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am 2013;42:677-695
70. Orban J-C, Maizière E-M, Ghaddab A, Van Obberghen E, Ichai C. Incidence and characteristics of acute kidney injury in severe diabetic ketoacidosis. PLoS One 2014;9:e110925
71. Atabek ME, Pirgon O, Oran B, Erkul I, Kurtoglu S. Increased cardiac troponin I concentration in diabetic ketoacidosis. J Pediatr Endocrinol Metab 2004;17:1077-1082
72. U.S. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims [Internet], 2009. Available from https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm193282.pdf. Accessed 26May 2017
73. Agency for Healthcare Research and Quality. About the National Quality Strategy [Internet], 2017. Available from http://www.ahrq.gov/workingforquality/about.htm. Accessed 26 May 2017
74. National Quality Forum. Patient-reported outcomes in performance measurement [Internet], 2012. Available from https://www.qualityforum.org/Publications/2012/12/Patient-Reported-Outcomes-in-Performance-Measurement.aspx. Accessed 26 May 2017
75. Burstin H, Johnson K. Getting to better care and outcomes for diabetes through measurement. Am J Manag Care 2016;22(Suppl. 4):SP145-SP146
76. Mohn J, Graue M, Assmus J, et al. Self-reported diabetes self-management competence and support fromhealthcare providers in achieving autonomyare negatively associated with diabetes distress in adults with type 1 diabetes. Diabet Med 2015;32:1513-1519
77. Johnson SR, Cooper MN, Davis EA, Jones TW. Hypoglycaemia, fear of hypoglycaemia and quality of life in childrenwith type 1 diabetes and their parents. Diabet Med 2013;30:1126-1131
78. Grandy S, Langkilde AM, Sugg JE, Parikh S, Sjöström CD. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. Int J Clin Pract 2014;68:486-494
79. Kamoi K, Miyakoshi M, Maruyama R. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2004;64:19-25